Department of Obstetrics and Gynecology, Hebei General Hospital, Shijiazhuang, Hebei, China.
Medicine (Baltimore). 2023 Aug 18;102(33):e34737. doi: 10.1097/MD.0000000000034737.
To systematically analyze the value of human epididymis protein 4 (HE4) and carbohydrate antigen 125 (CA125) in the diagnosis of endometrial cancer, so as to provide evidence-based medical evidence for the selection of serum tumor markers in the early screening of endometrial cancer.
We comprehensively searched relevant literature in the Cochrane Library, EMBASE, PubMed, Web of Science, CNKI, VIP, WanFang, and CBM from the date of establishment to November 31, 2021. Quality assessment of diagnostic accuracy studies 2 was applied to evaluate the quality of the included literature. We used Stata 16.0 to calculate the pooled sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odds ratio (DOR) and plot summary receiver operating characteristic curve, as well as to assess diagnostic accuracy using the area under the curve (AUC).
A total of 25 studies, including 1980 patients and 2345 controls, were included in this meta-analysis. The pooled SEN, SPE, PLR, NLR, DOR, and AUC of HE4 were 0.58 (95% CI 0.52-0.63), 0.95 (95% CI 0.92-0.97), 11.57 (95% CI 6.88-19.48), 0.45 (95% CI 0.39-0.51), 25.92 (95% CI 14.84-45.26), and 0.80 (95% CI 0.76-0.83), respectively. The pooled SEN, SPE, PLR, NLR, DOR, and AUC of CA125 were 0.41 (95% CI 0.34-0.49), 0.91 (95% CI 0.85-0.95), 4.55 (95% CI 2.73-7.58), 0.65 (95% CI 0.57-0.74), 7.03 (95% CI 3.92-12.62), and 0.68 (95% CI 0.64-0.72), respectively. The pooled SEN, SPE, PLR, NLR, DOR, and AUC of HE4 + CA125 were 0.67 (95% CI 0.60-0.73), 0.92 (95% CI 0.87-0.95), 8.59 (95% CI 5.32-13.86), 0.36 (95% CI 0.30-0.44), 23.80 (95% CI 13.86-40.86), and 0.85 (95% CI 0.82-0.88), respectively.
This Meta-analysis found that HE4 alone or in combination with CA125 showed better diagnostic efficacy than CA125, regardless of clinical stage and pathological type. HE4 + CA125 had slightly higher diagnostic efficiency than HE4, but did not show significant advantages. While the studies were heterogeneous, the credibility of the findings needs to be further confirmed by more homogeneous, prospective, and large sample size studies.
系统分析人附睾蛋白 4(HE4)和糖链抗原 125(CA125)在子宫内膜癌诊断中的价值,为子宫内膜癌早期筛查中血清肿瘤标志物的选择提供循证医学证据。
我们全面检索了 Cochrane 图书馆、EMBASE、PubMed、Web of Science、中国知网、维普、万方和中国生物医学文献数据库从建立到 2021 年 11 月 31 日的相关文献。应用诊断准确性研究 2 质量评估工具评估纳入文献的质量。我们使用 Stata 16.0 计算合并敏感性(SEN)、特异性(SPE)、阳性似然比(PLR)、阴性似然比(NLR)和诊断比值比(DOR),并绘制汇总受试者工作特征曲线,以及使用曲线下面积(AUC)评估诊断准确性。
共纳入 25 项研究,包括 1980 名患者和 2345 名对照,纳入了此荟萃分析。HE4 的合并 SEN、SPE、PLR、NLR、DOR 和 AUC 分别为 0.58(95%CI 0.52-0.63)、0.95(95%CI 0.92-0.97)、11.57(95%CI 6.88-19.48)、0.45(95%CI 0.39-0.51)、25.92(95%CI 14.84-45.26)和 0.80(95%CI 0.76-0.83)。CA125 的合并 SEN、SPE、PLR、NLR、DOR 和 AUC 分别为 0.41(95%CI 0.34-0.49)、0.91(95%CI 0.85-0.95)、4.55(95%CI 2.73-7.58)、0.65(95%CI 0.57-0.74)、7.03(95%CI 3.92-12.62)和 0.68(95%CI 0.64-0.72)。HE4+CA125 的合并 SEN、SPE、PLR、NLR、DOR 和 AUC 分别为 0.67(95%CI 0.60-0.73)、0.92(95%CI 0.87-0.95)、8.59(95%CI 5.32-13.86)、0.36(95%CI 0.30-0.44)、23.80(95%CI 13.86-40.86)和 0.85(95%CI 0.82-0.88)。
本荟萃分析发现,HE4 单独或与 CA125 联合检测的诊断效能优于 CA125,无论临床分期和病理类型如何。HE4+CA125 的诊断效率略高于 HE4,但并未显示出明显优势。虽然研究存在异质性,但需要更多同质、前瞻性、大样本量的研究来进一步证实研究结果的可信度。